PRR has less risk than SSN imo. SSN runs the same risk that most oil companies do - not hitting oil. At least PRR has a product very similar to a proven winner (DNDN).
Also PRR's potential long-term upside is squillions higher than SSN also.
If Provenge increases life-span of prostate cancer affected males by an average of 4 months only, and they have a market cap of approx $5B, what will PRR be worth if it extends the life of ovarian cancer patients by possibly a year or maybe two?
Also since there has been no negative side affects linked to CVac this will make it a lot easier to get through the FDA approval process.
PRR is potential huge win win win win win, SSN could be a win but not as big =P
My opinion only of course...
nothing to do with th sp, page-30
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.5¢ |
Change
0.015(4.69%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 33.5¢ | 32.0¢ | $1.303M | 3.974M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 29843 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 105523 | 4 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |